《大行报告》麦格理上调再鼎医药(09688.HK)目标价至1,500.36元 评级「跑赢大市」
麦格理发表研究报告指,再鼎医药(09688.HK)(ZLAB.US)与合作伙伴Novocure(NVCR.US)的Optune肿瘤电场疗法(Tumor Treating Fields,TTF)在治疗非小细胞肺癌患者的关键性3期临床试验中获得积极进展,刺激两家公司股价上扬。
该行指出,再鼎医药已获得Novocure授予Optune於大中华地区的独家开发权,大中华市场规模为美国市场的2.5倍,只需支付Novocure 10%至15%的特许权使用费,以及累计前期付款和里程碑费用少於1亿美元。麦格理将Optune峰值销售额预测由50亿元人民币提升至150亿元人民币,预期没有纳入国家医保药品目录,该疗法面对较少竞争及政策风险。
麦格理预期,Optune疗法的临床试验有望加快,将2022年收入预测上调约30%,受利好消息带动,将目标价提升85%至1,500.36元,并重申「跑赢大市」评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.